Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Jan;26(1):28-34.
doi: 10.1002/hup.1163.

Association between type-three metabotropic glutamate receptor gene (GRM3) variants and symptom presentation in treatment refractory schizophrenia

Jeffrey R Bishop  1 , Del D Miller, Vicki L Ellingrod, Timothy Holman
Affiliations

Association between type-three metabotropic glutamate receptor gene (GRM3) variants and symptom presentation in treatment refractory schizophrenia

Jeffrey R Bishop et al. Hum Psychopharmacol. 2011 Jan.

Abstract

Objective: Positive associations between polymorphisms in the type-three metabotropic glutamate receptor gene (GRM3) and the pathogenesis of schizophrenia as well as response to antipsychotic treatment have been reported. The objective of this study was to determine whether refractory psychiatric symptoms in antipsychotic non-responders are related to polymorphisms in GRM3.

Methods: Ninety-five treatment refractory schizophrenia participants were enrolled. Prior to a medication switch, global psychopathology and negative symptoms were rated. These participants were genotyped for seven markers in GRM3. Genotype associations with symptoms were assessed.

Results: Two markers in GRM3 (rs1989796 and rs1476455), were associated with the presence of refractory global symptoms as measured by the Brief Psychiatric Rating Scale (BPRS) Total scores. Participants with an rs1476455_CC genotype had significantly higher BPRS scores than A-carriers (55.1±10.4 vs. 48.3±9.2; F=7.6, p=0.0071). Additionally, participants with the rs1989796_CC genotype had significantly higher BPRS scores than T-carriers (50.1±5.7 vs. 55.8±10.5, F=7.1, p=0.0091). No evidence for significant associations with negative symptoms was observed.

Conclusions: Polymorphisms in the GRM3 gene may be associated with refractory global psychosis symptoms but not negative symptoms in persons with schizophrenia.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Linkage disequilibrium structure of GRM3
Linkage disequilibrium for GRM3 SNPs (displayed as D’) with solid spine D’>0.8 used to define haplotype blocks
Figure 2
Figure 2. GRM3 Variants and BPRS Total Scores
Analysis of variance and student's t-tests were used to compare mean BPRS values ± standard deviation across genotype groups.
See this image and copyright information in PMC

References

    1. Albalushi T, Horiuchi Y, Ishiguro H, et al. Replication study and meta-analysis of the genetic association of GRM3 gene polymorphisms with schizophrenia in a large Japanese case-control population. Am J Med Genet B Neuropsychiatr Genet. 2008;147:392–396. - PubMed
    1. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;21:263–265. - PubMed
    1. Bishop JR, Ellingrod VL, Moline J, Miller D. Association between the polymorphic GRM3 gene and negative symptom improvement during olanzapine treatment. Schizophr Res. 2005;77:253–260. - PubMed
    1. Bishop JR, Wang K, Moline J, Ellingrod VL. Association analysis of the metabotropic glutamate receptor type 3 gene (GRM3) with schizophrenia. Psychiatr Genet. 2007;17:358. - PubMed
    1. Cartmell J, Schoepp DD. Regulation of neurotransmitter release by metabotropic glutamate receptors. Journal of Neurochemistry. 2000;75:889–907. - PubMed

Publication types

Substances